vs
Nuvation Bio Inc.（NUVB）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
万物新生的季度营收约是Nuvation Bio Inc.的1.0倍（$43.2M vs $41.9M）
Nuvation Bio Inc.是一家临床阶段生物制药公司，专注于研发肿瘤靶向治疗药物，以满足难治性癌症领域未被满足的医疗需求，核心管线包含多款针对关键致癌通路的创新候选药物，核心业务及市场主要布局于北美地区。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
NUVB vs RERE — 直观对比
营收规模更大
RERE
是对方的1.0倍
$41.9M
损益表 — Q4 FY2025 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $41.9M | $43.2M |
| 净利润 | — | $7.3M |
| 毛利率 | — | — |
| 营业利润率 | -81.3% | — |
| 净利率 | — | 16.9% |
| 营收同比 | 633.1% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NUVBRERE
| Q4 25 | $41.9M | — | ||
| Q3 25 | $13.1M | — | ||
| Q4 24 | $5.7M | — | ||
| Q1 24 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q1 23 | — | $43.2M |
净利润NUVBRERE
| Q4 25 | — | — | ||
| Q3 25 | $-55.8M | — | ||
| Q4 24 | — | — | ||
| Q1 24 | $-14.8M | — | ||
| Q3 23 | $-19.6M | — | ||
| Q2 23 | $-20.6M | — | ||
| Q1 23 | — | $7.3M |
毛利率NUVBRERE
| Q4 25 | — | — | ||
| Q3 25 | 74.5% | — | ||
| Q4 24 | 26.2% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
营业利润率NUVBRERE
| Q4 25 | -81.3% | — | ||
| Q3 25 | -430.1% | — | ||
| Q4 24 | -944.5% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
净利率NUVBRERE
| Q4 25 | — | — | ||
| Q3 25 | -425.2% | — | ||
| Q4 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | 16.9% |
每股收益（稀释后）NUVBRERE
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q4 24 | $0.00 | — | ||
| Q1 24 | $-0.07 | — | ||
| Q3 23 | $-0.09 | — | ||
| Q2 23 | $-0.09 | — | ||
| Q1 23 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $529.2M | $228.0M |
| 总债务越低越好 | $47.2M | — |
| 股东权益账面价值 | $305.7M | $557.1M |
| 总资产 | $594.8M | $722.9M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资NUVBRERE
| Q4 25 | $529.2M | — | ||
| Q3 25 | $549.0M | — | ||
| Q4 24 | $502.7M | — | ||
| Q1 24 | $597.0M | — | ||
| Q3 23 | $619.3M | — | ||
| Q2 23 | $630.9M | — | ||
| Q1 23 | — | $228.0M |
总债务NUVBRERE
| Q4 25 | $47.2M | — | ||
| Q3 25 | $47.1M | — | ||
| Q4 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
股东权益NUVBRERE
| Q4 25 | $305.7M | — | ||
| Q3 25 | $325.9M | — | ||
| Q4 24 | $463.8M | — | ||
| Q1 24 | $594.0M | — | ||
| Q3 23 | $611.6M | — | ||
| Q2 23 | $624.6M | — | ||
| Q1 23 | — | $557.1M |
总资产NUVBRERE
| Q4 25 | $594.8M | — | ||
| Q3 25 | $601.6M | — | ||
| Q4 24 | $540.6M | — | ||
| Q1 24 | $613.1M | — | ||
| Q3 23 | $630.9M | — | ||
| Q2 23 | $641.4M | — | ||
| Q1 23 | — | $722.9M |
负债/权益比NUVBRERE
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-29.7M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流NUVBRERE
| Q4 25 | $-29.7M | — | ||
| Q3 25 | $-52.9M | — | ||
| Q4 24 | $-46.3M | — | ||
| Q1 24 | $-15.7M | — | ||
| Q3 23 | $-16.2M | — | ||
| Q2 23 | $-17.5M | — | ||
| Q1 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
